Advertisement

Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents

Published:April 23, 2022DOI:https://doi.org/10.1016/j.clgc.2022.04.010

      Abstract

      Purpose

      In an era of rapid expansion of FDA approvals for oral anticancer agents (OAAs), it is important to understand the factors associated with survival among real-world populations, which include groups not well-represented in pivotal clinical trials of OAAs, such as the elderly, racial minorities, and medically complex patients. Our objective was to evaluate patient- and provider-level characteristics’ associations with mortality among a multi-payer cohort of metastatic renal cell carcinoma (mRCC) patients who initiated OAAs.

      Methods

      This retrospective cohort study was conducted using data from the North Carolina state cancer registry linked to multi-payer claims data for the years 2004 to 2015. Provider data were obtained from North Carolina Health Professions Data System and the National Plan & Provider Enumeration System. Included patients were individuals with mRCC who initiated an OAA and survived ≥90 days after beginning treatment. We estimated hazard ratios (HR) and corresponding 95% confidence limits (CL) using Cox hazard models for associations between patient demographics, patient clinical characteristics, provider-level factors, and 2-year all-cause mortality.

      Results

      The cohort included 207 patients with mRCC who received OAAs. In multivariable models, clinical variables such as frailty (HR: 1.36, 95% CL: 1.11-1.67) and de novo metastatic diagnosis (HR: 2.63, 95%CL: 1.67-4.16) were associated with higher all-cause mortality. Additionally, patients solely on Medicare had higher adjusted all-cause mortality compared with patients with any private insurance (HR: 2.35, 95% CL: 1.32-4.18). No provider-level covariates investigated were associated with all-cause mortality.

      Conclusions

      Within a real-world population of mRCC patients taking OAAs, survival differed based on patient characteristics. In an era of rapid expansion of FDA approvals for OAAs, these real-world data underscore the continued importance of access to high-quality care, particularly for medically complex patients with limited resources.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel RL
        • Miller KD
        • Fuchs HE
        • Jemal A.
        Cancer statistics, 2022.
        CA Cancer J Clin. 2022; 72: 7-33https://doi.org/10.3322/CAAC.21708
        • Lindskog M
        • Wahlgren T
        • Sandin R
        • et al.
        Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations.
        Urol Oncol Semin Orig Investig. 2017; 35 (541.e15-541.e22)https://doi.org/10.1016/j.urolonc.2017.05.013
        • Gudbjartsson T
        • Thoroddsen A
        • Petursdottir V
        • Hardarson S
        • Magnusson J
        • Einarsson G V
        Effect of incidental detection for survival of patients with renal cell carcinoma: Results of population-based study of 701 patients.
        Urology. 2005; 66: 1186-1191https://doi.org/10.1016/j.urology.2005.07.009
        • Capitanio U
        • Bensalah K
        • Bex A
        • et al.
        Epidemiology of renal cell carcinoma.
        Eur Urol. 2019; 75: 74-84https://doi.org/10.1016/j.eururo.2018.08.036
        • Scoll BJ
        • Wong YN
        • Egleston BL
        • Kunkle DA
        • Saad IR
        • Uzzo RG.
        Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis.
        J Urol. 2009; 181: 506-511https://doi.org/10.1016/j.juro.2008.10.026
        • Wahlgren T
        • Harmenberg U
        • Sandström P
        • et al.
        Treatment and overall survival in renal cell carcinoma: A Swedish population-based study (2000-2008).
        Br J Cancer. 2013; 108: 1541-1549https://doi.org/10.1038/bjc.2013.119
        • Chow WH
        • Shuch B
        • Linehan WM
        • Devesa SS.
        Racial disparity in renal cell carcinoma patient survival according to demographic and clinical characteristics.
        Cancer. 2013; 119: 388-394https://doi.org/10.1002/cncr.27690
        • Bailey ZD
        • Krieger N
        • Agénor M
        • Graves J
        • Linos N
        • Bassett MT.
        Structural racism and health inequities in the USA: evidence and interventions.
        Lancet. 2017; 389: 1453-1463https://doi.org/10.1016/S0140-6736(17)30569-X
        • Padala SA
        • Barsouk A
        • Thandra KC
        • et al.
        Epidemiology of renal cell carcinoma.
        World J Oncol. 2020; 11: 79-87https://doi.org/10.14740/WJON1279
        • Schwartz K
        • Ruterbusch JJ
        • Colt JS
        • Miller DC
        • Chow WH
        • Purdue MP.
        Racial disparities in overall survival among renal cell carcinoma patients with young age and small tumors.
        Cancer Med. 2016; 5: 200-208https://doi.org/10.1002/cam4.578
        • Stafford HS
        • Saltzstein SL
        • Shimasaki S
        • Sanders C
        • Downs TM
        Robins sadler g. racial/ethnic and gender disparities in renal cell carcinoma incidence and survival.
        J Urol. 2008; 179: 1704-1708https://doi.org/10.1016/j.juro.2008.01.027
        • Rose TL
        • Deal AM
        • Krishnan B
        • et al.
        Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era.
        Cancer. 2016; 122: 2988-2995https://doi.org/10.1002/cncr.30146
        • Mafolasire A
        • Yao X
        • Nawaf C
        • et al.
        Racial disparities in renal cell carcinoma: a single-payer healthcare experience.
        Cancer Med. 2016; 5: 2101-2108https://doi.org/10.1002/cam4.755
        • Felder TM
        • Pena GD
        • Chapital BF.
        Disparities in cancer clinical trials: An analysis of comprehensive cancer control plans.
        Prev Chronic Dis. 2009; 6 (Accessed June 9, 2021)
        • Kaldany A
        • Blum KA
        • Paulucci DJ
        • et al.
        An evaluation of race, ethnicity, age, and sex-based representation in phase I to II renal cell carcinoma clinical trials in the United States.
        Urol Oncol Semin Orig Investig. 2018; 36 (363.e1-363.e6)https://doi.org/10.1016/j.urolonc.2018.05.006
        • Paul K
        • Sathianathen N
        • Dahm P
        • Le C
        • Konety BR.
        Variation in accrual and race/ethnicity reporting in urological and nonurological related cancer trials.
        J Urol. 2019; 202: 385-390https://doi.org/10.1097/JU.0000000000000294
        • Meyer AM
        • Olshan AF
        • Green L
        • et al.
        Big data for population-based cancer research: the integrated cancer information and surveillance system.
        N C Med J. 2014; 75: 265-269https://doi.org/10.18043/ncm.75.4.265
        • Gad MM
        • Saad AM
        • Al-Huseini MJ
        • Ruhban IA
        • Sonbol MB.
        Incidence and mortality of renal cell carcinoma in the U.S.: A SEER-based study investigating trends over the last four decades.
        J Clin Oncol. 2018; 36: 604https://doi.org/10.1200/jco.2018.36.6_suppl.604
        • Coppin C
        • Kollmannsberger C
        • Le L
        • Porzsolt F
        • Wilt TJ.
        Targeted therapy for advanced renal cell cancer (RCC): A Cochrane systematic review of published randomised trials.
        BJU Int. 2011; 108: 1556-1563https://doi.org/10.1111/j.1464-410X.2011.10629.x
        • Li P
        • Wong YN
        • Armstrong K
        • et al.
        Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
        Cancer Med. 2016; 5: 169-181https://doi.org/10.1002/cam4.574
      1. NC Health Workforce - Home. https://nchealthworkforce.unc.edu/. Accessed June 17, 2021.

        • Charlson ME
        • Pompei P
        • Ales KL
        • MacKenzie CR.
        A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation.
        J Chronic Dis. 1987; 40: 373-383https://doi.org/10.1016/0021-9681(87)90171-8
        • Faurot KR
        • Jonsson Funk M
        • Pate V
        • et al.
        Using claims data to predict dependency in activities of daily living as a proxy for frailty.
        Pharmacoepidemiol Drug Saf. 2015; 24: 59-66https://doi.org/10.1002/pds.3719
        • Racsa PN
        • Whisman TR
        • Worley K.
        Comparing two tyrosine kinase inhibitors for treatment of advanced renal cell carcinoma in Medicare and commercially insured patients.
        Current Medical Research and Opinion. 31. Taylor and Francis Ltd, 2015: 1933-1940https://doi.org/10.1185/03007995.2015.1081881
        • MacLean E
        • Mardekian J
        • Cisar LA
        • Hoang CJ
        • Harnett J.
        Real-world treatment patterns and costs for patients with renal cell carcinoma initiating treatment with sunitinib and pazopanib.
        J Manag Care Spec Pharm. 2016; 22: 979-990https://doi.org/10.18553/jmcp.2016.22.8.979
        • Vogelzang NJ
        • Pal SK
        • Ghate SR
        • et al.
        Real-world economic outcomes during time on treatment among patients who initiated sunitinib or pazopanib as first targeted therapy for advanced renal cell carcinoma: A retrospective analysis of medicare claims data.
        J Manag Care Spec Pharm. 2018; 24: 525-533ahttps://doi.org/10.18553/jmcp.2018.24.6.525
        • Fine JP
        • Gray RJ.
        A proportional hazards model for the subdistribution of a competing risk.
        J Am Stat Assoc. 1999; 94: 496-509https://doi.org/10.1080/01621459.1999.10474144
        • Handforth C
        • Clegg A
        • Young C
        • et al.
        The prevalence and outcomes of frailty in older cancer patients: a systematic review.
        Ann Oncol Off J Eur Soc Med Oncol. 2015; 26: 1091-1101https://doi.org/10.1093/ANNONC/MDU540
        • Mohile SG
        • Xian Y
        • Dale W
        • et al.
        Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries.
        J Natl Cancer Inst. 2009; 101: 1206-1215https://doi.org/10.1093/JNCI/DJP239
        • Shi Z
        • Peddi P
        • Burton G
        • Mills G
        • Shi R.
        Effect of postmastectomy radiation on survival of AJCC pN2/N3 breast cancer patients.
        Anticancer Res. 2016; 36: 261-270
        • Hing E
        • Burt CW.
        Vital and Health Statistics, Series. 2003; (13, No. 164 (1/2007).;)
        • Suh W
        • Master S
        • Liu L
        • Mills G
        • Shi R.
        The effect of payer status on survival of patients with prostate cancer.
        Cureus. 2021; 13https://doi.org/10.7759/cureus.13329
        • Salehi O
        • Vega EA
        • Lathan C
        • et al.
        Race, age, gender, and insurance status: a comparative analysis of access to and quality of gastrointestinal cancer care.
        J Gastrointest Surg. 2021; https://doi.org/10.1007/s11605-021-05038-6
        • Narang AK
        • Nicholas LH.
        Out-of-pocket spending and financial burden among medicare beneficiaries with cancer.
        JAMA Oncol. 2017; 3: 757-765https://doi.org/10.1001/jamaoncol.2016.4865
        • Dusetzina SB
        • Keating NL.
        Mind the gap: Why closing the doughnut hole is insufficient for increasing medicare beneficiary access to oral chemotherapy.
        J Clin Oncol. 2016; 34: 375-380https://doi.org/10.1200/JCO.2015.63.7736
        • Dean LT
        • George M
        • Lee KT
        • Ashing K.
        Why individual-level interventions are not enough: Systems-level determinants of oral anticancer medication adherence.
        Cancer. 2020; 126: 3606-3612https://doi.org/10.1002/cncr.32946
        • Shih YCT
        • Xu Y
        • Liu L
        • Smieliauskas F.
        Rising prices of targeted oral anticancer medications and associated financial burden on medicare beneficiaries.
        J Clin Oncol. 2017; 35https://doi.org/10.1200/JCO.2017.72.3742
        • Ramsey SD
        • Bansal A
        • Fedorenko CR
        • et al.
        Financial insolvency as a risk factor for early mortality among patients with cancer.
        J Clin Oncol. 2016; 34: 980-986https://doi.org/10.1200/JCO.2015.64.6620
        • Jordan AR
        • Wang J
        • Yates TJ
        • et al.
        Molecular targeting of renal cell carcinoma by an oral combination.
        Oncog 2020 95. 2020; 9: 1-13https://doi.org/10.1038/s41389-020-0233-0
        • Li P
        • Wong YN
        • Jahnke J
        • Pettit AR
        • Doshi JA.
        Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
        Cancer Med. 2018; : 75-86https://doi.org/10.1002/cam4.1262
        • Greer JA
        • Amoyal N
        • Nisotel L
        • et al.
        A systematic review of adherence to oral antineoplastic therapies.
        Oncologist. 2016; 21: 354-376https://doi.org/10.1634/theoncologist.2015-0405
        • Mathes T
        • Pieper D
        • Antoine SL
        • Eikermann M.
        Adherence influencing factors in patients taking oral anticancer agents: A systematic review.
        Cancer Epidemiol. 2014; 38: 214-226https://doi.org/10.1016/j.canep.2014.03.012
        • Sims JN
        • Yedjou CG
        • Abugri D
        • et al.
        Racial disparities and preventive measures to renal cell carcinoma.
        Int J Environ Res Public Health. 2018; 15https://doi.org/10.3390/ijerph15061089
        • Kaye D
        • Wilson L
        • Spees LP
        • et al.
        Provider and hospital characteristics associated with initiation of, adherence to and survival after starting oral anti-neoplastic agents for metastatic renal cell carcinoma.
        in: NCI Symposium on Cancer Health Disparities. 2021